Results 151 to 160 of about 38,538 (308)
Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less ...
Utkarsh Goel +9 more
wiley +1 more source
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka +5 more
wiley +1 more source
Targeting of peripheral blood T lymphocytes [PDF]
Bolhuis, R.L.H. (Reinder) +2 more
core +1 more source
We report the first successful orthotopic engraftment of human esophageal squamous cell carcinoma in immunosuppressed microminipigs and demonstrate high‐contrast near‐infrared fluorescence endoscopic detection using EGFR‐targeted cetuximab. This large‐animal model bridges preclinical imaging research and future clinical translation in esophageal cancer.
Takanori Miyake +14 more
wiley +1 more source
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro +12 more
wiley +1 more source
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese +12 more
wiley +1 more source
ABSTRACT Adult hemophagocytic lymphohistiocytosis (HLH) is a rare, life‐threatening syndrome triggered by various conditions. A nationwide study of the incidence and outcomes of HLH in Denmark over 23 years (2000–2023) was performed. Adults (≥ 18 years) with HLH and triggering diseases were identified in the Danish National Patient Registry and/or the ...
Mads Okkels Birk Lorenzen +8 more
wiley +1 more source
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello +7 more
wiley +1 more source
ABSTRACT Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti‐CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes ...
Emiliano Barbieri +11 more
wiley +1 more source
Vascular Endothelial Growth Factor/Angiopoietin-2 Bispecific Antibody-Induced Vascular Normalization: From Basic Mechanisms to Therapeutic Applications in Breast Cancer. [PDF]
Li M +6 more
europepmc +1 more source

